BrayantconT

MPSS 🤏🏼

[BrayantconT @brayantcon]

Y aunque no estés conmigo.
Te agradezco por cambiarme; por hacerme mejor hijo, mejor hermano, mejor amigo, mejor persona.

[UroToday.com @urotoday]

Advanced #ProstateCancer - Doublet vs triplet: Who needs additional treatment intensification for #mHSPC? Presentation by @jackiebrown_MD @WinshipAtEmory. #AUA26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/jpEYiZ2cmr @AmerUrological

[Nature Human Behaviour @NatureHumBehav]

How to design effective scientific figures https://t.co/2r8WVAqP18

[Dra. María Natalia Gandur Quiroga @nataliagandur]

⭐ How to treat older patients with high-risk and locally advanced prostate cancer

@OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin

Presented by @DrRanaMcKay

🔹 Beautiful, clear and highly practical presentation — a key topic in daily clinical care

🔹 Focus:
Personalizing treatment in older patients by balancing efficacy, toxicity, comorbidities and quality of life
🔹 Key insights:
• Chronological age ≠ biological age → frailty assessment is essential
• Geriatric tools (e.g. G8) help identify patients needing deeper evaluation
• Treatment decisions are multidimensional: local therapy, ADT use, intensity and duration
• RT often better tolerated across age groups vs surgery in selected patients
• ARPI use → increased CV risk, especially in real-world populations
• Optimal ADT duration remains nuanced → benefit vs toxicity trade-off

🔹 Clinical implications:
• Avoid both undertreatment and overtreatment
• Incorporate frailty, comorbidities and patient goals into decisions
• Move toward individualized, biology + patient-centered care
🔹 Take-home:
In older patients, the key is not “less treatment” —
but the right treatment for the right patient
👏 Excellent talk — thank you!

@BertrandTOMBAL
@EAntonarakis
@DrRanaMcKay
@LoebStacy
@AarmstrongDuke
@DrSpratticus
@piet_ost
@stefanofanti4
@declangmurphy

[Dra. María Natalia Gandur Quiroga @nataliagandur]

⭐ Are we overtreating patients in the mpMRI / PSMA PET era?

@OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin

Presented by Derya Tilki

🔹 Excellent overview on the strengths and limits of modern imaging

🔹 Key messages:
🔹 1. MRI-derived EPE and seminal vesicle invasion are independently associated with biochemical recurrence and metastatic failure
🔹 2. MRI-based T-staging remains clinically useful — but terminology and reporting need standardization
🔹 3. PSMA PET/CT improves detection of local tumor extension and nodal disease in selected settings
🔹 4. Combining mpMRI + PSMA PET may better define dominant and non-dominant lesions
🔹 5. Imaging–biopsy discordance remains a key challenge in treatment planning
🔹 6. More accurate imaging can improve selection — but may also increase the risk of overtreatment if not interpreted carefully
🔹 Take-home:
Modern imaging should refine decisions, not replace clinical judgment, pathology and multidisciplinary discussion.
@declangmurphy @RenuEapen @DrYukselUrun @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @Uromigos @EUplatinum @EANM_NucMed @ESTRO_RT @Uroweb

[Baris Turkbey MD @radiolobt]

📢 Exciting Read for Radiologists and Urologists🚀

📚Just came across this fantastic educational article in @RadioGraphics “PRECISE Version 2: Essential Tips for Prostate Cancer MRI Reporting”

🔔This paper is a must-read for anyone involved in prostate MRI!

✅It provides clear, practical guidance on using the updated PRECISE v2 system to standardize reporting for patients on active surveillance.

👍Key highlights include refined scoring for assessing disease stability/progression, helpful checklists, case examples, and tips to reduce ambiguity in serial MRI interpretation!

💡Whether you’re a radiologist fine-tuning your reports, a urologist discussing imaging with your patients, or a trainee building your skills — this valuable resource makes complex concepts more approachable and clinically impactful!

🥇Congrats to @giga_fra and the entire team for this nice work!

🔗 Full article: https://t.co/aDDs0diGET

#Radiology #ProstateCancer #MRI #ActiveSurveillance #RadioGraphics

[IJIR: Your Sexual Medicine Journal @yoursexmedjour]

At #EAU26, S. Luján Marco presented “From PI-RADS to Te-RADS,” highlighting how testicular MRI biomarkers may help reduce futile surgery @Uroweb
More on non-obstructive azoospermia: https://t.co/DAan1Ab3iB
#IJIR #Urology #MaleInfertility #Andrology #NOA #TesticularMRI

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

A MUST-READ!

This is probably one of my most important papers where I try to teach how to fish rather than offer fish.

How I Read a Clinical Trial Report?

BG’s primer for Busy Clinicians.

Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful.

https://t.co/HJhZlsBpU2

[MUSC Urologic Oncology Program @MUSC_UroOnc]

If you’re attending #AUA26 and would like to learn more, feel free to DM us.

@EMW2000 @MatveyTsivian @JayChavaliMD @JL_Drerup @SES_AUA @UroOnc @SUO_YUO @LuisMedinaMD

[Felipe Couñago PhD @fcounago]

🚀 New paper out!

ARPI intensification in non-metastatic HSPC.

📄 https://t.co/8hNQn8Xi2O

Congrats to all co-authors 👏
Special thanks to Patricia Willisch & Beatriz Vázquez

#ProstateCancer

[Adam B. Weiner, MD @Adam_Weiner535]

🎯 BULLSEYE trial: ¹⁷⁷Lu-PSMA-617 in oligometastatic hormone-sensitive #prostatecancer:

@TheLancetOncol

📈 Median PFS: 25 months vs just 5 months for deferred ADT
💥 83% had ≥50% PSA drop (24% complete response!)
✅ Well tolerated — HRQoL maintained
⏳ ADT-free survival: 26 months

Could this be a manner to delay hormone therapy? 🤔

@UrologyTimes @urotoday @renalandurology

🔗https://t.co/1GGxFSQ9BO

[UroToday.com @urotoday]

PSMA PET in #ProstateCancer drug development: Regulatory challenges and considerations. Presentation by William Maguire, MD @FDA. #PSMA26 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/vrYvVtOhLc @PSMAconference #2026PSMAandBeyond

[Diego Barreiro @DBarreiro4]

El FIN de la recaída bioquímica.
El PET con Cobre detecta más del doble de lesiones que el PET con Galio en la recaída post prostatectomia.
En lugar de hablar de recaída bioquímica podremos detectar el sitio de recurrencia y darle al paciente una nueva oportunidad de rescate.

[Óscar Rodríguez Faba @RodriguezFaba]

This month in @actasurologicas https://t.co/RZEYl3IK5r

📊 T1 renal cell carcinoma in Spain 🇪🇸

n=1121 | 30 centres

🔹 Surgery 82.6%
🔹 PN 65% (74.5% in cT1a)
🔹 MIS 92.3%

⚠️ RN still frequent in cT1b → technical complexity & access issues

[UroToday.com @urotoday]

Analysis of a posterior surgical technique in robotic-assisted radical prostatectomy. @jimhumd @WeillCornell joins @zklaassen_md @GACancerCenter to discuss the PATENTS technique for robotic prostatectomy on UroToday > https://t.co/MQO0MkahHb

[BrayantconT @brayantcon]

Hoy soy todo, mañana no existo.

[Matt Cooperberg @dr_coops]

More insights from @MSKCancerCenter re: N+ #prostatecancer. Confirming PSMA PET ≠ PLND, PLND alone is not commonly curative, tx needs to be multimodal. #GU26 @SeanFletcherMD

[Adam B. Weiner, MD @Adam_Weiner535]

🚀 MDT in oligometastatic #ProstateCancer 🚀

👉WOLVERINE IPD meta-analysis in @TheLancetOncol

🧪 7 randomized trials, 574 pts
📉 MDT → ↓ progression, ↓ radiographic progression, ↓ time to CRPC
🔁 Consistent benefit across SOC (obs, ADT, ARPI)
🛡️ Low toxicity, short treatment courses
⚖️ OS not definitive; but this is the strongest evidence yet to integrate MDT

👏 @ChadTangMD @piet_ost

🔗 to study https://t.co/OtIHw4RGgV
🔗 to editorial https://t.co/aeWi3Wx0ms

@PCFnews @urotoday @UrologyTimes

[Juan Gómez Rivas @JGomezRivas]

📃 | El futuro del cribado del cáncer de próstata en Europa 🇪🇺

El cribado del cáncer de próstata está cambiando.

🆕 ¿Qué propone Europa?
Desde 2022, la Unión Europea recomienda avanzar hacia programas organizados de cribado, incorporando por primera vez el cáncer de próstata, basados en riesgo y no en PSA indiscriminado.

🔍 ¿Qué es PRAISE-U?
El proyecto PRAISE-U liderado por la European Association of Urology @Uroweb , desarrolla un modelo de detección precoz inteligente, combinando:
•✅ PSA
•✅ Estratificación de riesgo (calculadoras)
•✅ Resonancia magnética
•❌ Evitando sobrediagnóstico y sobretratamiento

🇪🇸 Experiencia española: Galicia y Manresa
Dos modelos distintos, un mismo objetivo:
✔️ Cribado organizado
✔️ Coordinación entre salud pública, atención primaria y urología
✔️ Equidad, trazabilidad y eficiencia

📌 Resultados clave
•Galicia: 7.000 hombres invitados en <1 año
•Manresa: cribado desde atención primaria con alta accesibilidad
•La RM se consolida como herramienta clave antes de biopsiar

🧠 Mensaje clave
➡️ El debate ya no es “PSA sí o no”
➡️ Es “cómo detectar antes, mejor y solo a quien lo necesita”

Este trabajo demuestra que el cribado poblacional del cáncer de próstata es posible, sostenible y centrado en el riesgo, si hay planificación, tecnología y colaboración entre niveles asistenciales

#PRAISEU #Cribado #CáncerDePróstata #Urología

https://t.co/5xcNG48IzR

@JesusMorenosier @heinvanpoppel @Praiseu_org